Clinical Impact of Not Achieving Recommended Dose on Duration of Atomoxetine Treatment in Adults with Attention‐Deficit/Hyperactivity Disorder

by Clemow, David B., Nyhuis, Allen W., Robinson, Rebecca L.
Published in CNS Neurosci Ther (2016)

Atomoxetine Effects on Executive Function as Measured by the BRIEF-A in Young Adults with ADHD: A Randomized, Double-Blind, Placebo-Controlled Study

by Adler, Lenard A., Clemow, David B., Williams, David W., Durell, Todd M.
Published 2014

A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbidities

by Clemow, David B, Bushe, Chris, Mancini, Michele, Ossipov, Michael H, Upadhyaya, Himanshu
Published in Neuropsychiatr Dis Treat (2017)

Real‐World Dosing Patterns of Atomoxetine in Adults with Attention‐Deficit/Hyperactivity Disorder

by Kabul, Samaneh, Alatorre, Carlos, Montejano, Leslie B., Farr, Amanda M., Clemow, David B.
Published in CNS Neurosci Ther (2015)

Atomoxetine Increased Effect over Time in Adults with Attention‐Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double‐Blind, Placebo‐Controlled,...

by Wietecha, Linda A., Clemow, David B., Buchanan, Andrew S., Young, Joel L., Sarkis, Elias H., Findling, Robert L.
Published in CNS Neurosci Ther (2016)

Lasmiditan mechanism of action – review of a selective 5-HT(1F) agonist

by Clemow, David B., Johnson, Kirk W., Hochstetler, Helen M., Ossipov, Michael H., Hake, Ann M., Blumenfeld, Andrew M.
Published in J Headache Pain (2020)